Eli Lilly and CompanyLLYNYSE
Loading
Operating Expenses Over TimeExpanding
Percentile Rank100
3Y CAGR+23.4%
5Y CAGR+16.0%
Year-over-Year Change
Expenses from normal business operations (SG&A, R&D, etc.)
3Y CAGR
+23.4%/yr
vs +5.3%/yr prior
5Y CAGR
+16.0%/yr
Recent acceleration
Acceleration
+18.1pp
Accelerating
Percentile
P100
Near historical high
vs 5Y Ago
2.1x
Strong expansion
Streak
7 yr
Consecutive growthExpanding
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $24.92B | +30.3% |
| 2024 | $19.12B | +17.6% |
| 2023 | $16.25B | +22.6% |
| 2022 | $13.26B | +1.4% |
| 2021 | $13.07B | +10.4% |
| 2020 | $11.85B | +2.1% |
| 2019 | $11.60B | +7.5% |
| 2018 | $10.79B | -4.3% |
| 2017 | $11.28B | -3.1% |
| 2016 | $11.64B | - |